已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression

医学 肝细胞癌 免疫疗法 肿瘤科 内科学 外科 癌症
作者
Tsung‐Hao Liu,San‐Chi Chen,Kun‐Ming Rau,Li‐Chun Lu,Po‐Ting Lin,Yung‐Yeh Su,Wei Teng,Shiue‐Wei Lai,Ren‐Hua Yeh,Tsui-Mai Kao,Pei‐Chang Lee,Chi-Jung Wu,Chien‐Hung Chen,Chih‐Hung Hsu,Shi‐Ming Lin,Yi‐Hsiang Huang,Li‐Tzong Chen,Ann‐Lii Cheng,Ying‐Chun Shen
出处
期刊:Liver cancer [S. Karger AG]
卷期号:13 (5): 509-521
标识
DOI:10.1159/000536549
摘要

Introduction: The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized. Methods: Patients with advanced HCC who received immune checkpoint inhibitor (ICI)-based immunotherapy and achieved durable responses were retrospectively included. A durable response was defined as partial response (PR) or stable disease (SD) per RECIST 1.1 for more than 8 months after initiation of immunotherapy. Oligoprogression and polyprogression were defined as progression at ≤3 and >3 lesions, respectively. Results: A total of 91 durable responders (63 PR and 28 SD) were identified. The majority had chronic viral hepatitis (n = 69, 75.8%). Forty-seven (51.6%) and 44 (48.4%) patients received the index immunotherapy as first-line and second- or beyond-line therapy, respectively. Fifty-four (59.3%) patients subsequently developed progression, with a predominant pattern of oligoprogression (66.7%). The median overall survival (OS) was 46.2 months (95% CI: 34.1–58.3). For patients with subsequent progression, employment of locoregional therapy (LRT) for progression was associated with prolonged OS (univariate analysis: hazard ratio [HR] 0.397, p = 0.009; multivariate analysis: HR 0.363, p = 0.050). Patients with oligoprogression who received LRT showed longer median OS than those who did not (48.4 vs. 20.5 months, p < 0.001). In contrast, the median OS of patients with polyprogression who received LRT was not different from those without LRT (27.7 vs. 25.5 months, p = 0.794). Conclusion: Approximately 60% of the post-immunotherapy durable responders of HCC subsequently develop progression. Proactive LRT may further rescue patients who develop subsequent oligoprogression. Prospective studies are mandatory to clarify the proper management of durable responders with subsequent progression.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
白日梦我发布了新的文献求助10
4秒前
麻瓜小禾子完成签到,获得积分20
5秒前
于冷松发布了新的文献求助10
7秒前
水晶鞋完成签到 ,获得积分10
8秒前
Omni完成签到,获得积分10
11秒前
碧蓝巧荷完成签到 ,获得积分10
11秒前
白日梦我完成签到,获得积分20
14秒前
14秒前
杳鸢应助Omni采纳,获得10
17秒前
于冷松完成签到,获得积分10
21秒前
21秒前
24秒前
25秒前
Wander_Li发布了新的文献求助10
27秒前
叶听枫发布了新的文献求助10
29秒前
小羊的夏天完成签到,获得积分10
32秒前
嗯哼举报积极嚓茶求助涉嫌违规
34秒前
叶听枫完成签到,获得积分10
35秒前
36秒前
yxw完成签到,获得积分10
37秒前
大胆机器猫完成签到,获得积分10
37秒前
小航完成签到 ,获得积分10
38秒前
Cruffin完成签到 ,获得积分10
39秒前
诚心凝蝶完成签到,获得积分10
39秒前
Ava应助不安毛豆采纳,获得10
39秒前
40秒前
王娟完成签到,获得积分10
41秒前
酷酷凌旋完成签到,获得积分20
43秒前
HS完成签到,获得积分10
44秒前
脑洞疼应助lumu采纳,获得10
47秒前
48秒前
pany应助海莲采纳,获得10
49秒前
54秒前
56秒前
57秒前
yuyu完成签到,获得积分10
58秒前
1分钟前
18746005898完成签到 ,获得积分10
1分钟前
星辰大海应助简单的雅蕊采纳,获得10
1分钟前
高分求助中
Earth System Geophysics 1000
Semiconductor Process Reliability in Practice 650
Studies on the inheritance of some characters in rice Oryza sativa L 600
Medicina di laboratorio. Logica e patologia clinica 600
《关于整治突出dupin问题的实施意见》(厅字〔2019〕52号) 500
Mathematics and Finite Element Discretizations of Incompressible Navier—Stokes Flows 500
Language injustice and social equity in EMI policies in China 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3207671
求助须知:如何正确求助?哪些是违规求助? 2856984
关于积分的说明 8108052
捐赠科研通 2522565
什么是DOI,文献DOI怎么找? 1355756
科研通“疑难数据库(出版商)”最低求助积分说明 642234
邀请新用户注册赠送积分活动 613602